BioLingus, a Swiss biotech company incorporated in the Cayman Islands, filed for an IPO on Friday. The company intends to trade on the Nasdaq Capital Market under the ticker symbol “SUBL.” It said it expected to offer 3 million ordinary shares at $15 to $16 apiece. In its IPO filing, BioLingus said its research was focused on the oral delivery of medications, via the area under the tongue. The company said it was in the development stage, with no revenue, and had a net loss of $1.4 million for the fiscal year ending April 30, 2022.
